310 related articles for article (PubMed ID: 15156439)
1. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases.
Peloquin CA; Berning SE; Nitta AT; Simone PM; Goble M; Huitt GA; Iseman MD; Cook JL; Curran-Everett D
Clin Infect Dis; 2004 Jun; 38(11):1538-44. PubMed ID: 15156439
[TBL] [Abstract][Full Text] [Related]
2. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
de Jager P; van Altena R
Int J Tuberc Lung Dis; 2002 Jul; 6(7):622-7. PubMed ID: 12102302
[TBL] [Abstract][Full Text] [Related]
3. Aminoglycoside toxicity in infants and children.
McCracken GH
Am J Med; 1986 Jun; 80(6B):172-8. PubMed ID: 3524215
[TBL] [Abstract][Full Text] [Related]
4. [Dosing aminoglycosides once a day].
Blaser J
Schweiz Med Wochenschr Suppl; 1996; 76():39S-48S. PubMed ID: 8677418
[TBL] [Abstract][Full Text] [Related]
5. Iron chelators protect from aminoglycoside-induced cochleo- and vestibulo-toxicity.
Song BB; Sha SH; Schacht J
Free Radic Biol Med; 1998 Jul; 25(2):189-95. PubMed ID: 9667495
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
[TBL] [Abstract][Full Text] [Related]
7. Ototoxicity and pharmacokinetically determined dosages of amikacin in granulocytopenic cancer patients.
Danhauer FJ; Fortner CL; Schimpff SC; deJongh CA; Wesley MN; Wiernik PH
Clin Pharm; 1982; 1(6):539-43. PubMed ID: 7185540
[TBL] [Abstract][Full Text] [Related]
8. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
Sweileh WM
Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328
[TBL] [Abstract][Full Text] [Related]
9. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series.
Davis KK; Kao PN; Jacobs SS; Ruoss SJ
BMC Pulm Med; 2007 Feb; 7():2. PubMed ID: 17319962
[TBL] [Abstract][Full Text] [Related]
10. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?
Soulsby N; Bell S; Greville H; Doecke C
Intern Med J; 2009 Aug; 39(8):527-31. PubMed ID: 19220547
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin.
Lerner SA; Schmitt BA; Seligsohn R; Matz GJ
Am J Med; 1986 Jun; 80(6B):98-104. PubMed ID: 3524221
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of amikacin nephrotoxicity in the hematology/oncology population.
Kiel PJ; Lo M; Stockwell D; Patel GP
Am J Ther; 2008; 15(2):131-6. PubMed ID: 18356633
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of aminoglycoside antibiotics.
Clark CH
Mod Vet Pract; 1977 Jul; 58(7):594-8. PubMed ID: 329097
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of single daily dose gentamicin in stem cell transplantation.
Warkentin D; Ippoliti C; Bruton J; Van Besien K; Champlin R
Bone Marrow Transplant; 1999 Jul; 24(1):57-61. PubMed ID: 10435736
[TBL] [Abstract][Full Text] [Related]
15. The evolution of aminoglycoside therapy: a single daily dose.
Deamer RL; Dial LK
Am Fam Physician; 1996 Apr; 53(5):1782-6. PubMed ID: 8623702
[TBL] [Abstract][Full Text] [Related]
16. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.
Kim MJ; Bertino JS; Erb TA; Jenkins PL; Nafziger AN
J Clin Pharmacol; 2004 Jul; 44(7):696-707. PubMed ID: 15199074
[TBL] [Abstract][Full Text] [Related]
17. Vestibulotoxicity: a risk of home aminoglycoside therapy.
Saunders JE
J Okla State Med Assoc; 2005 Dec; 98(12):596-600. PubMed ID: 16425609
[TBL] [Abstract][Full Text] [Related]
18. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
[TBL] [Abstract][Full Text] [Related]
19. [Clinical efficacy, nephrotoxicity and ototoxicity of amikacin].
Federspil P; Schindler K; Weich C; Tiesler E; Schätzle W; Ziegler M
Infection; 1979; 7(2):81-7. PubMed ID: 374277
[TBL] [Abstract][Full Text] [Related]
20. [Aminoglycoside-induced nephrotoxicity].
Fabrizii V; Thalhammer F; Hörl WH
Wien Klin Wochenschr; 1997 Nov; 109(21):830-5. PubMed ID: 9454436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
